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Summary
Human cytomegalovirus (HCMV) is a ubiquitous pathogen that is poten-
tially pathogenic in immunosuppressed individuals and pregnant females
during primary infection. The HCMV envelope glycoprotein B (gB) facili-
tates viral entry into all cell types and induces a potent immune response.
AD-2 epitope is a highly conserved linear neutralizing epitope of gB and a
critical target for antibodies; however, only 50% of sero-positive individu-
als make IgG antibodies to this site and IgA responses have not been fully
investigated. This study aimed to compare IgG and IgA responses against
gB and the AD-2 epitope in naturally exposed individuals and those
receiving a recombinant gB/MF59 adjuvant vaccine. Thus, vaccination of
sero-positive individuals improved pre-existing gB-specific IgA and IgG
levels and induced de novo gB-specific IgA and IgG responses in sero-neg-
ative recipients. Pre-existing AD-2 IgG and IgA responses were boosted
with vaccination, but de novo AD-2 responses were not detected. Natu-
rally exposed individuals had dominant IgG responses towards gB and
AD-2 compared with weaker and variable IgA responses, although a sig-
nificant IgA binding response to AD-2 was observed within human breast-
milk samples. All antibodies binding AD-2 contained kappa light chains,
whereas balanced kappa/lambda light chain usage was found for those
binding to gB. V region-matched AD-2-specific recombinant IgG and IgA
bound both to gB and to AD-2 and neutralized HCMV infection in vitro.
Overall, these results indicate that although human IgG responses domi-
nate, IgA class antibodies against AD-2 are a significant component of
human milk, which may function to protect neonates from HCMV.
Keywords: AD-2 epitope; glycoprotein B; human cytomegalovirus; im-
munoglobulin A.
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous patho-
gen that affects approximately 85% of the global human
population.1 HCMV infection is resolved naturally in
healthy individuals due to a rigorous immune response,
but this opportunistic pathogen remains a substantial
cause of morbidity and occasional mortality in immuno-
compromised patients such as transplant recipients,2 in
AIDS patients3 and in fetuses.4,5 Consequently, this clini-
cal burden has led to the application of antiviral thera-
pies,6 antibody-based treatments7 and a high priority
Abbreviations: Ab, antibody; AD, antigenic determinant; ARPE-19, human retinal pigment epithelial cells; C, constant region;
DMEM, Dulbecco’s modified Eagle’s minimal essential medium; ELISA, enzyme-linked immunosorbent assay; FACS, fluores-
cence-activated cell sorting; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; gB, glycoprotein B; HCMV, human cytome-
galovirus; HEK 293, human embryonic kidney cells; HFF, human foreskin fibroblasts; IE, immediate early; IgA, immunoglobulin
A; IgG, immunoglobulin G; mAbs, monoclonal antibodies; MOI, multiplicity of infection; OD, optical density; PBS, phosphate-
buffered saline; pHC, immunoglobulin heavy chain plasmid; pLC, immunoglobulin light chain plasmid; sIgA, secretory IgA; Vh,
heavy chain variable region; Vk, light chain variable region
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placed on vaccine development for HCMV intervention.8
Limitations of these therapies and prophylactics have
necessitated a deeper understanding of the HCMV life
cycle, viral structural determinants and host immune cor-
relates of protection. This in turn has led to the develop-
ment in recent years of numerous monoclonal antibodies
(mAbs) and novel vaccine candidates for HCMV.
Although hyperimmune globulin preparations have
shown mixed success in the prevention of congenital
HCMV infection9 and HCMV disease in solid organ
transplantation,10 the increasing use of mAbs as therapeu-
tics and prophylactics for human diseases11 has spurred
interest in the development of antiviral mAbs, including
for HCMV.7 Numerous mAbs are under preclinical devel-
opment and target diverse structural components of the
virus that are required for entry into cells. The major
viral targets of mAbs and host humoral immunity are the
glycoprotein B (gB) and the pentamer complex consisting
of gH, gL, pUL128, pUL130 and pUL131A. Abs to these
viral components are known to block infection of fibrob-
lasts, epithelial cells, endothelial cells, macrophages and
dendritic cells.12,13 Most mAbs studied are of the IgG iso-
type despite increasing evidence of the importance of IgA,
particularly at mucosal surfaces.14 Humans have two sub-
classes of IgA, with serum consisting of 90% of IgA1 and
10% IgA2, whereas in mucosal samples such as saliva and
breastmilk, the ratio is closer to 40:60.14 Furthermore,
multiple molecular forms of IgA exist. In human serum,
IgA is predominantly monomeric, whilst the mucosal
secretory IgA (sIgA) is dimeric. It is predicted that IgA
mAbs will be used more frequently in the future and rival
the therapeutic and prophylactic uses of IgG.
HCMV gB is a highly conserved glycoprotein among
the herpesvirus family and plays a critical role in infectiv-
ity and cell-to-cell spread being the viral determinant crit-
ical for membrane fusion during entry.15 Based on this
critical role of gB in facilitating virus entry and being a
well-described immune system target, gB is a promising
candidate for development of vaccines and Ab-mediated
therapies. Five antigenic determinants or epitopes (termed
AD-1, AD-2, AD-3, AD-4 and AD-5) located on gB have
been described.16 The conformational AD-1 epitope was
originally described as the major epitope,17 inducing pro-
duction of IgG Abs in all infected individuals; however,
not all of the AD-1 epitope binding Abs are neutraliz-
ing.18 Conversely, only 50% of sero-positive individuals
are capable of generating AD-2-specific Abs in spite of
their potent neutralizing capability19 and all human mAbs
identified to this epitope are of the IgG subclass and have
been shown to consist of kappa light chains.16,20,21 The
use of kappa light chains is thought to restrict binding
properties of human Abs to simpler epitope structures
such as AD-2.22 More recently, the AD-4 and AD-5 epi-
topes, which are conserved and immunogenic and induce
potent neutralizing Abs, have been identified on gB.16
The AD-3 epitope was identified within the gB cytoplas-
mic domain and is a target of non-neutralizing Abs.16
Thus, the knowledge of gB epitope-based Abs has
increased in recent years and coupled with the develop-
ment of recombinant gB as a subunit vaccine23 demon-
strates its importance.
At present, there is no licensed vaccine for HCMV;
however, the recombinant gB subunit vaccine has been
evaluated extensively in recent years through numerous
clinical trials. Studies have demonstrated immunogenicity
and safety, including the boosting of pre-existing immu-
nity in those already infected with HCMV.24–28 Recombi-
nant gB vaccination has displayed partial efficacy through
reductions in primary maternal infection, which would
likely reduce the incidence of congenital infections,29 and
was effective at reducing viraemia when administered to
kidney and liver transplant patients – particularly in sero-
negative vaccine recipients.30 Despite these encouraging
clinical trials where 50% vaccine efficacy was observed,
the mechanistic correlate of protection for the gB vaccine
remains elusive. Studies of sera taken from HCMV-sero-
negative recipients of the gB vaccine demonstrated lim-
ited evidence of neutralizing antibodies31,32 although in
the transplant study, challenge of vaccinees with an organ
from a HCMV-sero-positive donor did reveal a rapid
accumulation of gB-specific neutralizing antibodies post-
transplant in some patients. In contrast, individuals natu-
rally infected with HCMV do generate neutralizing anti-
body responses directed against epitopes within gB
including AD-2. Interestingly, two separate studies have
suggested that AD-2 responses in naturally infected indi-
viduals are an important correlate of protection,33,34 and
vaccination with gB will boost this response in the 50%
of individuals who have generated it in response to prior
natural infection.35
Much of these prior studies have focused on the IgG
response to gB and thus not fully assessing the entire
repertoire of antibody responses to HCMV and vaccina-
tion. In this study, we have investigated the contribu-
tion of IgA alongside IgG Abs to gB and AD-2
generated by vaccination with recombinant gB and in
healthy adults naturally exposed to HCMV. We report
data obtained for serum IgG and IgA responses to gB
and AD-2 in gB/MF59 adjuvant vaccine recipients,
matched human serum and saliva samples from indi-
viduals naturally exposed to HCMV, human breastmilk
samples and recombinant Abs specific for AD-2 format-
ted as human IgA or IgG. Our data indicate that whilst
human IgG responses to gB and AD-2 predominate,
substantial IgA responses were detected, particularly in
breastmilk. The demonstration that recombinant mono-
clonal IgA antibodies directed against AD-2 can neutral-
ize HCMV infection in vitro argues that IgA antibodies
should be considered another component of protective
immunity to HCMV via AD-2.




The following HCMV-specific antigens were used: gB
recombinant protein, stock concentration 0.8 mg/ml, was
also used as the vaccine immunogen, provided by Sanofi
Pasteur; AD-2 is a short linear peptide made by solid-
phase synthesis, stock concentration 1 mg/ml; and
sequence SHRANETIYNTTLKYGDKL (minimal epitope
shown bold) was synthesized and purchased from Alta
Biosciences, UK.
Human sample collection, processing and storage
Human serum samples were obtained from a prior vac-
cine trial of recombinant gB from HCMV and MF59
adjuvant trial, performed on a group of solid organ trans-
plant patients (NCT00299260) enrolled in a phase 2 ran-
domized and double-blinded placebo-controlled study.30
Samples were obtained from placebo or vaccinated volun-
teers at day 0 (baseline and first dose) and day 56
(1 month afters econd dose), were blinded and were
stored at 80°C until use.
Twenty-four healthy adult volunteer participants each
donated both blood and saliva samples for matching pur-
poses. Blood samples (5 ml) were collected in sterile
tubes (without anticoagulant) and then left to clot. The
samples were centrifuged at room temperature at 280 g
for 15 min, and the serum fraction was separated from
the clot. Serum was stored at 80°C prior to analysis.
Volunteers also donated 2 ml of saliva, which was cen-
trifuged at 5040 g for 10 min at 4°C to remove cells and
debris. The supernatant was collected and stored at
80°C prior to analysis. Participants were anonymized by
coding the samples provided, thereby maintaining patient
confidentiality, safety and respect. Exclusion criteria
included the following: volunteers suffering from any
acute or chronic disease; age <18 years; and pregnancy.
The study was approved by the Research Ethics Commit-
tee of the School of Human Sciences of London
Metropolitan University.
Fourteen human breastmilk samples, originally col-
lected from milk bank at Queen Charlotte’s and Chelsea
Hospital, Imperial College Healthcare NHS Trust, were
kindly provided by the Microbiology Research Unit of
London Metropolitan University. Each sample was vor-
texed briefly to dissolve fats and divided into four ali-
quots and stored at 80°C before analysis.
ELISA
ELISA was performed as described earlier20,33 with the
modification that coating with antigens to determine
specific binding (AD-2 peptides or recombinant gB) or
capture antibodies to determine levels of IgG and IgA
(anti-human kappa and anti-human lambda) diluted in
PBS was performed overnight at 4°C. Antigens and cap-
ture antibodies were coated at a final concentration of
1 µg/ml. In all cases, blocking was performed with 5%
non-fat dry milk in PBS containing 0.1% Tween-20
(PBST milk) at 37°C for 2 h. Samples diluted in PBST
milk were added, and plates were incubated overnight at
4°C. Peroxidase-labelled secondary Abs to human IgG,
human IgA, human kappa and human lambda chains
(Southern Biotechnology Associates) were diluted in
PBST milk and added to plates, which were incubated at
37°C for 2 h. Colour was developed following the addi-
tion of 3,30,5,50-tetramethylbenzidine (TMB; Thermo
Fisher) and stopped with 0.1 M HCl. Washing was per-
formed between steps using Skatron SkanWasher 300,
and the optical density at 450 nm was determined using
an OMEGA plate reader (BMG Labtech).
Human recombinant monoclonal antibodies
8F9, QG1 and FA9 are three human monoclonal IgG,
which bind to the AD-2 epitope of gB.20 The L and H
chain V region cDNA of each was inserted into the
human Ig expression vectors, pLC-huCj, pHC-huCa1
and pHC-huCc1 expression vectors,36 for expression as
human IgA1 and human IgG1 mAbs. L chain and H
chain plasmids containing 8F9, QG1 and FA9 cDNA were
propagated in E. coli after transformation and selection
from LB–ampicillin plates, where single colonies were
chosen and grown overnight at 37°C. Plasmids were iso-
lated from bacterial cultures using Qiagen plasmid kits.
Restriction digest was performed to confirm the plasmid
integrity followed by Sanger sequencing to confirm cor-
rect Ab V regions. Plasmid concentrations were deter-
mined by NanoDrop UV spectrophotometry.
Transient transfection of HEK 293 cells
HEK 293 cells were seeded in a 6-well plate at 6.25 9 105
cells per well in 2 ml of Dulbecco’s modified Eagle’s min-
imal essential medium (DMEM; Invitrogen) supple-
mented with 2% penicillin–streptomycin (Invitrogen) and
10% FCS (Invitrogen) the day before transfection. On the
day of transfection, media were replaced with 0.5 ml of
Opti-MEM. For each well of cells, 5 µl of Lipofectamine
3000 reagent was diluted into 125 µl of Opti-MEMTM and
gently mixed. 5 µg of plasmid DNA (equal amounts of
pLC and pHC) was diluted in Opti-MEMTM including
5 µl of P3000 reagent and mixed well. Diluted Lipofec-
tamine 3000 reagent was combined with each tube of
diluted DNA (1:1 ratio) and incubated at room tempera-
ture for 10–15 min to form DNA–Lipofectamine 3000
reagent complexes. After incubation, the complexes were
added to each well containing cells and gently mixed by
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rocking the plate back and forth. After 4–5 h of incuba-
tion, DMEM-FCS was added and cells were incubated at
37°C at 5% CO2 concentration for 4–5 days with media
harvested and added each day. Supernatants were verified
for monoclonal antibody expression by ELISA prior to
further experiments.
HCMV neutralization assays
Human foreskin fibroblasts (HFFs) were seeded in 96-well
cell culture plate, and a confluent monolayer was allowed
to form. Virus stocks (TCID50 of 5.44 9 106/ml of high
passage Merlin strain) were diluted and added to infect the
cells at a MOI of 1. Next, 100 µl of each mAb (10 µg/ml)
was mixed with virus in triplicate, titrated and incubated
for 30 min at 37°C. The antibody–virus mixture was then
added to HFFs and incubated for 1 h at 37°C. The inocu-
lum was removed, and growth medium was added and
incubated overnight at 37°C before the cells were fixed with
cold, 100% ethanol (20°C) for 30 min, washed three
times with PBS and stained for IE gene expression using
anti-IE (Millipore; 1:1000) for 1 h at room temperature.
Unbound antibody was removed by washing three times
with PBS, and reaction wells were stained with goat anti-
mouse Alexa Fluor 568 nm (Life Technologies; 1:2000) for
1 h at room temperature. Nuclei were counterstained with
40,6-diamidino-2-phenylindole (DAPI). Unbound antibody
was removed by washing three times with PBS, and per-
centage infection was enumerated by immunofluorescence
imaging using Hermes WiScan instruments. A similar
method was employed using human retinal pigment
epithelial cells (ARPE-19) as the target of infection. Here,
we pre-mixed IgA1 mAbs (diluted 1:3) with the epithelial–
tropic strain of HCMV (TB40/e) before following the pro-
cedure described above for HFFs.
Flow cytometry analysis
Mouse myeloma NS0 cells and engineered NS0 cells stably
expressing the N-terminus of gB (residues 28-100) con-
taining the AD-2 epitope on their surface as described20
were suspended at ~106/ml in PBS containing 0.5% FCS
(FACS buffer) and then incubated with Abs for 30 min on
ice. Following incubation, the cells were washed with ice-
cold FACS buffer and then stained with diluted anti-hu-
man к chain FITC conjugate (Southern Biotechnology
Associates) for 30 min on ice in dark. Fluorescence was
analysed using a Guava 8HT cytometer, and the data were
analysed using FCS Express (De Novo software).
Statistical analyses
The analysis of data obtained was performed using
GraphPad Prism software. Data were first evaluated for
normal distribution to ascertain which statistical tests
should be applied. Statistical differences between the
mean OD values of antibodies at each dilution were
obtained from the Mann–Whitney test (ns, not signifi-
cant; *P < 0.05; **P < 0.005; ***P < 0.001; and
****P < 0.0001). Correlations were assessed by Spear-
man’s correlation and the r values and P values stated.
RESULTS
IgG and IgA responses to HCMV gB and AD-2 in
HCMV-sero-positive volunteers
Serum and saliva samples were obtained from 24 healthy
adult volunteers and screened for binding levels of IgG
and IgA to recombinant gB and the AD-2 epitope (Fig-
ure 1). Four samples were found to be negative as defined
by lack of serum IgG to gB when diluted 1:100, and these
samples were used to define the positive–negative cut-off
values for each Ab isotype binding to gB and AD-2 (Fig-
ure S1). For serum samples, IgG responses to gB were the
strongest with 20 positive samples (83.3% positive),
whereas the IgA responses were much more variable and
titrated out earlier than IgG although 19 samples
(79.16%) remained positive at 1:100 dilution (Figure 1A).
Serum IgG and IgA responses to AD-2 were weaker than
those to gB, with 16 samples IgG positive (66.66%), but
only four samples were determined as IgA positive at
1:100 dilution (20.8%) (Figure 1A). In general, the saliva
results (Figure 1B) display similar trends as those
observed with serum (Figure 1A). For gB, binding of IgA
was significantly weaker than IgG, and for AD-2, a
reduced frequency of positive samples was noted.
Representation of these data as scatterplot correlations
allowed us to compare individual IgG and IgA responses
against gB and AD-2 together (Figure 2). The strongest cor-
relations were observed with serum and saliva IgG responses
with maximal r values of 0.5656 and 0.7433, respectively
(Figure 2A). Correlations were lower for both serum and
saliva IgA responses (Figure 2B). These data most likely
reflect the differences in relative levels of each Ab isotype
between saliva and serum, with serum containing excess IgG
over IgA and saliva more balanced levels.37 These data are
also consistent with AD-2 responses being extremely vari-
able between individuals, whereas gB responses are reliably
stronger, reflecting the number of possibilities that poly-
clonal Abs have to bind the much larger gB molecule with
its additional available epitopes. Thus, only a proportion of
individuals generate IgG and IgA to the AD-2 epitope
despite being considered HCMV-sero-positive.
IgG and IgA responses to HCMV gB and AD-2 in
recombinant gB vaccine recipients
To compare natural infection with vaccination, we inves-
tigated human serum samples obtained from a prior
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vaccine trial of recombinant gB from HCMV30 for IgG
and IgA responses to HCMV gB and the AD-2 epitope.
Findings for IgG responses had been previously pub-
lished33 and demonstrated that levels of IgG to AD-2 cor-
related with a reduced incidence of viraemia in HCMV-
sero-positive transplant recipients. Importantly, whilst the
gB vaccine could boost pre-existing IgG responses against
AD-2, de novo IgG responses were not detected27. We
therefore decided to investigate whether these data with
IgG were reflected with the IgA isotype response. Figure 3
displays our findings investigating serum IgG and IgA
responses to gB and the AD-2 epitope for placebo and
vaccine recipients, stratified by HCMV-sero-positive sta-
tus. The gB/MF59 vaccine boosted gB binding Abs in
sero-positive recipients only in the IgA responses, which
reached statistical significance (Figure 3A). IgG and IgA
responses to AD-2 showed a trend towards boosting (Fig-
ure 3A) but did not reach statistical significance. How-
ever, if individuals were stratified into AD-2 responders
(based on one sample being considered positive according
to cut-off values) and removed the AD-2 non-responders
(no positive AD-2 sample), the vaccine boosted pre-exist-
ing AD-2 responses (Figure S2). Thus, AD-2 responses do
not develop in all subjects and gB vaccination can boost
these responses only in sero-positive subjects who have
already developed AD-2 responses after natural infection.
In sero-negative gB vaccine recipients, robust IgG and
variable IgA responses to gB were also detected. However,
consistent with previous studies, IgG responses to the lin-
ear AD-2 epitope were not induced by vaccine and simi-
lar results were obtained with IgA (Figure 3B). Therefore,
vaccination with gB does not elicit de novo AD-2
responses in sero-negative or sero-positive subjects. In
conclusion, these new findings assessing IgA responses in
response to gB/MF59 match those previously found for
IgG.33 Finally, analysis of individuals’ responses revealed
that all the IgA-positive samples to AD-2 were also IgG-
positive.
Human milk IgG and IgA display different binding
profiles to gB and AD-2
Thus far, we could detect IgA responses against both gB
and AD-2 in natural infection and that vaccination pro-
moted IgA responses against gB. The studies in both sera
and saliva also suggested that the IgG response predomi-
nated over IgA, so we next turned our attention to
human antibody responses to HCMV found in breastmilk
samples. Similar to human serum and saliva samples, we
determined binding responses to gB and AD-2 with data
presented as dot plots and correlations in Figure 4. Four-
teen samples were investigated. Again, we used four sero-
IgG
****
**** **** **** **** **** ****
**** ****












































Figure 1. Human IgG and IgA bind HCMV gB and AD-2. ELISA to determine IgG and IgA binding to gB and AD-2 epitope of HCMV in (A)
human serum (n = 24) and (B) human saliva (n = 24). All samples were diluted as indicated, and data are represented as OD450 nm values of
triplicate determinations of three independent experiments. Horizontal dotted lines representing positive/negative cut-off values for negative gB
and negative AD-2 samples were based on IgG gB-negative samples (n = 4). Statistical differences comparing the mean OD450 nm values of IgG
and IgA binding to gB and AD-2 epitope at each dilution were obtained from the Mann–Whitney test (ns, not significant; ****P < 0.0001)
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negative breastmilk samples to determine positive nega-
tive cut-off values for the ELISA (Figure S3). For the
remaining 10 samples, we observed similar binding pro-
files of IgG and IgA to gB that titrated out at 1:500 (Fig-
ure 4A). Interestingly, for AD-2 binding, we found that
IgA responses were significantly stronger than IgG (Fig-
ure 4A) in contrast to those observed with serum and sal-
iva. The scatterplot correlations comparing individual
samples binding response to gB and AD-2 confirmed
these data and demonstrated that the best (r = 0.5637) is
seen with IgA responses (Figure 4B). Thus, the IgG/IgA
picture in breastmilk was different to that seen in saliva
and sera.
Light chain usage by serum antibodies binding gB
and AD-2
Following the characterization of isotype responses in
multiple compartments, we next sought to investigate the













































































































Figure 2. Scatterplot correlations of individual samples displaying IgG and IgA binding to both HCMV gB and the AD-2 epitope. ELISA data
displaying comparative IgG (A) and IgA (B) binding to gB and AD-2 epitope of HCMV in each sample of human serum (n = 24) and human
saliva (n = 24). Samples were diluted as indicated, and data are represented as OD450 nm values of triplicate determinations of three indepen-
dent experiments. Horizontal and vertical dotted lines representing positive/negative cut-off values for negative gB and negative AD-2 samples,
respectively, were based on IgG gB-negative samples (n = 4). Correlation coefficients (Spearman’s) and statistical significance for each set of
determinations comparing serum or saliva IgG and IgA binding to gB and AD-2 epitope are displayed within each graph
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characterized the contribution of the light chains to these
antibodies found in human serum. We found that anti-
bodies binding to gB displayed a balanced usage of kappa
(j) and lambda (k) light chains, whereas the antibodies
binding to AD-2 were restricted to j chain usage (Fig-
ure 5A). These data are confirmed within the scatterplot
correlations comparing individual responses to gB and
AD-2 where the use of j light chains displays r values
ranging from 0.5234 to 0.5804, whereas k light chain
usage does not display significant values (Figure 5B).
Similar results were observed when testing human milk
samples for light chain usage in antibodies binding to gB
and AD-2 (Figure S4), suggesting that both IgG and IgA
binding to AD-2 prefers the use of j chains.
AD-2-specific recombinant antibodies expressed as
IgG1 and IgA1
Using this information, we next expressed three human
recombinant antibodies specific for AD-220 as both
human IgG1 and IgA1 using immunoglobulin expression
vectors (pHC-huCc1, pHC-huCa1) and mammalian cell
expression systems.36 Our data from Figure 5 and previ-
ous V region sequencing analyses20 demonstrated that all
Abs binding AD-2 used j light chains, and therefore, we
could construct intact V region-matched human Abs by
coexpression with pLC-huCj expression vectors. Figure 6
displays expression and binding data for recombinant
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Figure 3. gB vaccination induces IgG and IgA responses to gB and AD-2 in sero-positive recipients. Serum samples obtained from the recombi-
nant gB vaccination trial were analysed for IgG and IgA binding to gB and AD-2 by ELISA. Individuals were stratified into (A) sero-positive
(IgG+to gB) and (B) sero-negative (IgG- to gB). Statistical differences between the mean OD values of day 0 and 56 of vaccine recipients for IgG
and IgA for binding to gB and AD-2 epitope were obtained from the Mann–Whitney test (ns, not significant; *P < 0.05; ****P < 0.0001). Pla-
cebo groups showed no significant differences
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these antibodies as both IgG1 and IgA1 and measured
levels in culture supernatants and compared IgG1 and
IgA1 binding against both gB and AD-2. All were effec-
tively expressed and bound to gB and AD-2 as both IgG1
and IgA1 except for clone FA9 IgA1 (Figure 6A). We
therefore decided to focus further studies on 8F9 and
QG1 clones and normalize their concentrations as IgG1
and IgA1. These analyses revealed significantly stronger
binding of IgG1 to both gB and AD-2 as compared to
IgA1 (Figure 6B). These data confirm that V region-
matched recombinant Abs show constant region-depen-
dent binding differences with IgG1 consistently stronger
than IgA1, particularly when analysing binding to AD-2.
Recombinant IgG1 and IgA1 binding to cell-
associated gB and neutralization of HCMV in vitro
To confirm the data observed in ELISA binding experi-
ments, we performed investigations using cells engi-
neered to express an N-terminal fragment of gB20 and
compared AD-2-specific recombinant IgG and IgA
binding. These experiments were designed to mimic
what might be expected to occur for recognition via
the AD-2 epitope of cell-associated gB. Figure 7A and
Figure S5 display the flow cytometric analysis of
recombinant IgG1 and IgA1 binding to cells expressing
a fragment of gB. Binding of the 8F9 and QG1 clones
expressed as IgG1 was observed, but very limited bind-
ing was detected when using the V region-matched
IgA1 variants. These data confirm that seen in ELISA
experiments (Figure 6B) where reduced binding of the
IgA1 clones to AD-2 was noted. Despite the apparent
reduced IgA1 binding to AD-2, we found that the IgA1
was still able to neutralize HCMV infection in vitro
(Figure 7B). In particular, 8F9 IgA1 neutralized at
lower concentrations than 8F9 IgG1 (IC50 0.2 vs. 1 µg/
ml) and completely neutralized at 2 µg/ml. In contrast,
QG1 IgA1 was less effective compared with its IgG1
counterpart (IC50 3 vs. 0.8 µg/ml) and was unable to
completely neutralize HCMV. Importantly, IgA1 anti-
bodies 8F9 and QG1 also neutralized HCMV infection
of epithelial cells (Figure 7C). These results suggest that
the structural form of the AD-2 epitope (within recom-
binant gB, synthetic peptide, cell-surface expression,
native virion) can influence recognition by Abs and, in
















































Figure 4. Human milk-derived IgG and IgA bind HCMV gB and AD-2. (A) ELISA to determine IgG and IgA binding to gB and AD-2 epitope
of HCMV in human breastmilk samples (n = 14). Samples were diluted as indicated, and data are represented as OD450 nm values of triplicate
determinations of three independent experiments. Horizontal dotted lines representing positive/negative cut-off values for negative gB and nega-
tive AD-2 samples were based on IgG gB-negative samples (n = 4). Statistical differences comparing the mean OD450 nm values of IgG and IgA
binding to gB and AD-2 epitope at each dilution in part A were obtained from the Mann–Whitney test (ns, not significant; **P < 0.01;
***P < 0.001). (B) Scatterplot correlations of individual undiluted samples displaying IgG and IgA binding to both HCMV gB and the AD-2 epi-
tope. Horizontal and vertical dotted lines are shown representing positive/negative cut-off values for negative gB and negative AD-2 samples,
respectively, and were based on IgG gB-negative samples (n = 4). Correlation coefficients (Spearman’s) and statistical significance for each set of
determinations comparing IgG or IgA binding to gB and AD-2 epitope are displayed within each graph
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DISCUSSION
In this study, through a comparison of human IgG and
IgA responses to HCMV gB and AD-2 epitope found in
serum, saliva and breastmilk, we have investigated a
potential role for IgA antibodies against HCMV infection.
Despite relatively weak IgA responses and reduced fre-
quency of binding to AD-2 in matched human serum
and saliva samples, we detected strong binding of IgA
from breastmilk and recombinant IgA1 to AD-2 bound
effectively to both gB and AD-2 and neutralized HCMV
in vitro. Interestingly, we found that gB/MF59 vaccination
boosted both IgG and IgA binding to gB and AD-2 but
only with pre-existing responses for the latter. Our data
are supportive of an important role for human IgA to gB
and AD-2 in the protective immune response against
HCMV and warrant further investigation in gB vaccine
trials.
Recombinant HCMV gB is under evaluation as a sub-
unit vaccine to protect against congenital HCMV
0·0


































































Figure 5. Human antibodies binding HCMV AD-2 epitope preferentially use kappa (j) light chains. (A) ELISA to determine light chain usage of
Ig’s binding to gB and AD-2 epitope of HCMV human serum (n = 24). Horizontal dotted lines representing positive/negative cut-off values for
negative gB and negative AD-2 samples were based on the IgG gB-negative samples (n = 4). Statistical differences comparing the mean
OD450 nm values for kappa (j) and lambda (k) chain use at each dilution were obtained from the Mann–Whitney test (ns, not significant;
****P < 0.0001). (B) ELISA data displaying comparative j and k usage in Ig’s binding to gB and AD-2 epitope of HCMV in serum samples.
Horizontal and vertical and dotted lines representing positive/negative cut-off values for negative gB and negative AD-2 samples, respectively,
were based on the IgG gB-negative samples (n = 4). Correlation coefficients (Spearman’s) and statistical significance for each set of determina-
tions comparing j or k usage in Ig’s binding to gB and AD-2 epitope are displayed above each graph
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infection and transplant-related viraemia. Serum Abs
obtained from one such vaccine trial30 were used to
probe the IgA responses to gB and AD-2 epitope follow-
ing gB/MF59 vaccination. Our results with IgA responses
are consistent with those previously reported for IgG33
with vaccination inducing de novo IgA responses to gB in
sero-negative recipients and boosting IgA responses in
sero-positive recipients. In fact, gB vaccination reliably
and significantly induced serum IgA responses to gB in
both sero-positive and sero-negative recipients, suggesting
that this component of the HCMV immune response is
induced via the vaccine regimen. Prior analyses of epi-
tope-specific gB IgG responses in this transplant cohort
revealed that AD-2 Abs were linked with reduced
viraemia and suggested that this might be a correlate of
protection in HCMV-sero-positive solid organ transplant
recipients.33 Importantly, vaccination with gB boosted
these pre-existing IgG AD-2 responses but failed to
induce de novo responses. We now show that this boost-
ing effect also occurred in those individuals with pre-ex-
isting IgA to AD-2. The key question is whether IgA
responses against AD2 are protective – however, given the
number of patients with IgA AD-2 responses, it was not
possible to perform a retrospective clinical analysis of
outcome. However, our in vitro neutralization data argue
that IgA responses against AD-2 could be protective.
Thus, we propose that future studies of the humoral
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2 µg/ml 0·2 µg/ml 0·1 µg/ml1 µg/ml +ve ctrl
QG1 AD-2 binding
–ve ctrl
Figure 6. Recombinant antibodies expressed as human IgG and IgA bind gB and AD-2 epitope of HCMV. (A) Expression of monoclonal recom-
binant antibodies QG1 IgG1, QG1 IgA1, 8F9 IgG1, 8F9 IgA1, FA9 IgG1 and FA9 IgA1 by transient transfection and ELISA of undiluted culture
supernatants and binding to gB and AD-2. +ve control, diluted human serum; –ve control, undiluted culture supernatant from untransfected
cells; unrelated IgG and IgA are control human mAbs. (B) Binding and titration of concentration-matched mAbs QG1 IgG1 (black bars), QG1
IgA1 (grey bars), 8F9 IgG1 (black bars), 8F9 IgA1 (grey bars) to gB and AD-2 epitope of HCMV represented as OD values with human serum as
positive control and unrelated IgG and unrelated IgA as negative control. Statistical differences between the mean OD values of IgG and IgA
expression and for binding to gB and AD-2 epitope were obtained from the Mann–Whitney test (**P < 0.01; ****P < 0.0001)
ª 2020 The Authors. Immunology published by John Wiley & Sons Ltd, Immunology10
SIDDIQUI et al.
ongoing vaccine studies particularly those proposing to
use AD-2 as the immunogen.
Our data are consistent with previous studies that have
shown that IgG Abs to AD-2 in humans are known to be
composed of a restricted set of Vh and Vj regions,20,38
which could be one reason why such Abs are rare and
outnumbered by Abs binding other gB epitopes.19 This
feature of AD-2 Abs of both the IgG and IgA isotypes
can also explain the low frequency of de novo synthesis
of AD-2 Abs following gB vaccination. Our current inves-
tigations have revealed new structural constraints of Abs
binding to AD-2. Here, we demonstrated that light chain
usage in AD-2-specific Abs is restricted to use of j light
chains, whereas Abs binding to other epitopes of gB can
consist of either j or k light chains. This feature of Abs
binding short linear peptides is not unique to AD-2 and
has been demonstrated previously, with the preferential
use of j light chains a reflection of limited antigenic
complexity.22 This could indicate another immune eva-
sion mechanism of HCMV to restrict immune responses
to an important conserved epitope required by the virus
for cell entry.
To confirm our data with polyclonal Abs and to estab-
lish the significance of IgA to AD-2, we created three V
region-matched AD-2 specific mAbs as both IgG1 and
IgA1. Our results with these mAbs demonstrated that
even though IgG1 binding was stronger towards synthetic
AD-2 peptide, membrane-associated AD-2 epitope and
recombinant gB, as compared to IgA1 binding, we found
that IgA1 binding AD-2 could efficiently neutralize
HCMV in vitro. Thus, crucially, the IgA antibodies were
clearly functional against HCMV. It is difficult to deter-
mine the contribution of IgA within polyclonal prepara-
tions where competition between IgG and IgA might be
expected; therefore, our mAb studies are important to
establish the relative importance of IgA responses to
HCMV. Our data may reflect the natural binding prefer-
ences among the different Ab isotypes including C region
effects on affinity and avidity for antigens observed previ-
ously.39 Most importantly, our data demonstrate that IgA
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Figure 7. AD-2 specific IgA mAbs neutralize HCMV in vitro. (A) Isotype-matched mAbs 8F9 (IgG1 and IgA1) and QG1 (IgG1 and IgA1) bind-
ing to NS0 cells engineered to express the N-terminal fragment of gB (NS0-gBNT) as measured by flow cytometry. Grey filled histogram, sec-
ondary Ab alone: mAb – 2 µg/ml (black line), 1 µg/ml (dark grey line) and 0.2 µg/ml (light grey line). (B) Neutralization assays for HCMV
infection of human foreskin fibroblasts (HFFs) represented as percentage of cells infected with high passage Merlin strain of HCMV. 8F9 IgG1,
8F9 IgA1, QG1 IgG1 and QG1 IgA1 were titrated with data shown as representative of 2 independently performed experiments. (C) Neutraliza-
tion assay for HCMV (TB40/e) infection of human epithelial cells (ARPE-19) represented as infection relative to no Ab control (assigned 1.0).
8F9 IgA1 and QG1 IgA1 were diluted 1:3 and assayed in triplicate. Statistical differences between the mean values of each mAb compared with
no mAb for each concentration were obtained from the Mann–Whitney test (no asterisk is not significant; *P < 0.05; **P < 0.01; ***P < 0.001)
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is capable of binding to AD-2, particularly in the absence
of IgG, and strengthen our observations that IgA in
human breastmilk displays superior binding over IgG.
It is important that human IgA binding AD-2 was cap-
able of neutralizing HCMV in vitro. In fact, the best neu-
tralizing recombinant clone was 8F9 expressed as human
IgA1. It displayed improved neutralizing capabilities over
its IgG1 counterpart, requiring lower concentrations to
achieve significant neutralization effects. Surprisingly, this
particular Ab clone did not display significant binding to
AD-2 in various assays, demonstrating the complexity of
interpreting these data where antigens in different bioana-
lytical formats are used. Nevertheless, these data verify
that the AD-2 epitope can be targeted for the develop-
ment of highly efficient mAbs for HCMV treatment and
support recent studies investigating this potential. The
AD-2-specific mAb TRL345 has produced promising pre-
clinical results including the potential for preventing con-
genital transmission.40,41 Another AD-2 binding mAb,
TCN-202, has undergone phase 1 clinical trial and proved
to be well tolerated, but further trials have not yet pro-
ceeded. The 8F9 mAb described here and previously20 is
also a prototype biotherapeutic that will be investigated
in further studies.
Our experiments also used matched human serum and
saliva samples to compare the Abs for binding to gB and
AD-2 epitope. Similar to the gB vaccine study, a major
observation was the much weaker IgA response to gB and
AD-2 epitope when compared to IgG responses. This
occurred in both serum and saliva samples; in fact, serum
results were generally indistinguishable from those found
with saliva. This is somewhat surprising when considering
that normal serum IgG levels are significantly higher than
IgA, whereas in saliva, the opposite is true and less com-
petition from IgG would be expected. Nevertheless, our
results confirm that IgG is the dominant isotype of Abs
to gB and AD-2 in both serum and saliva from healthy
individuals naturally exposed to HCMV. These data are
in agreement with another study showing sensitive and
specific detection of IgG to gB in saliva.42 Conversely, we
found that human breastmilk Abs binding AD-2 were lar-
gely of the IgA isotype, whilst a balanced IgG and IgA
response to gB was observed. In fact, we observed IgA
AD-2 responses in 90% of positive human breastmilk
samples as opposed to much reduced frequency of IgG
responses. These data may reflect the different structural
properties of IgA that exists as a monomer in serum, as
does IgG, and dimeric or polymeric mucosal secretory
IgA that is predominantly found in breastmilk.43 Thus,
differences in the relative concentration and structure of
IgG and IgA between serum, saliva and breastmilk may
account for their variable binding affinity to AD-2. More
generally, this preponderance of IgA antibodies against
HCMV in breastmilk may be an important component of
passive immunity transferred between mother and child.
An additional important observation in the study was
that all HCMV-sero-positive individuals (defined as pro-
ducing IgG to gB) did not necessarily produce IgG or IgA
to AD-2. In fact, samples that contained IgG to gB dis-
played variable AD-2 binding with a reduced proportion
of those considered positive. These data are in agreement
with previous studies that have shown approximately
50% of individuals produce antibodies to AD-2.44,45 It is
speculated that AD-2 binding Abs are restricted in nature
due to limited structural constraints allowing antigen
recognition.19,46 This phenomenon can also help explain
the reduced frequency and ability of serum and salivary
IgA to bind AD-2. In fact, we observed true IgA AD-2
response in only one saliva sample and just four serum
samples out of a total of twenty. However, human breast-
milk studies indicated a dominant IgA response to AD-2
epitope as compared to IgG in sero-positive individuals.
We have demonstrated in breastmilk significant human
IgA responses to AD-2, an important neutralizing epitope
of HCMV, and determined that IgA binding is capable of
neutralizing HCMV in vitro. This may indicate a function
for neonatal protection against HCMV conferred by IgA
binding AD-2. Studies using saliva and serum samples,
including those obtained from a recombinant gB vaccine
trial, displayed much weaker IgA binding to AD-2, which
we conclude is due to competition with the higher IgG
levels present. In sero-negative gB vaccine recipients, we
could not detect IgA or IgG to AD-2, despite the genera-
tion of both IgA and IgG to gB with this vaccination regi-
men, demonstrating the immunodominance of other gB
epitopes. The protective immune response to HCMV is
clearly very complex, requiring both cellular and humoral
immunity.47 It is also well known that Ab responses to
the AD-2 epitope of gB are extremely variable and incon-
sistent. We report that IgA to AD-2 is, numerically, a
minor component of HCMV humoral immunity but is
protective and warrants further investigation, in particular
with respect to induction via vaccination strategies. The
AD-2 epitope can also be targeted for the development of
potent therapeutic mAbs as an effective treatment option
for HCMV, including those of the IgA isotype. Targeted
Ab cocktails consisting of several Abs with different speci-
ficities and properties may therefore find utility in HCMV
treatment.
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Figure S1. Cut off graphs of four human serum sam-
ples determined to be negative at 1:100 dilution for IgG
to gB, IgA to gB, IgG to AD-2 and IgA to AD-2. Cut offs
were calculated at each dilution based on the 2 standard
deviations above the mean of all the OD values obtained
from replicate assays of all 4 samples. Tables demonstrate
cut off values obtained for all samples at each dilution for
the same 4 samples in various assays.
Figure S2. Serum samples from seropositive recipients
of the recombinant gB vaccination trial were analysed for
IgG and IgA binding to AD-2 by ELISA. Only individuals
where one sample is considered positive (according to cut
off values obtained in SFig 1) are shown. Statistical differ-
ences between the mean OD values of day 0 and day 56
of placebo and vaccine recipients for IgG and IgA for
binding to AD-2 epitope were obtained from Mann-
Whitney test (ns, not significant; *P < 0.05). Placebo
groups for IgA showed no positive samples and are not
included.
Figure S3. Cut off graphs of four undiluted human
breast milk samples determined to be negative for IgG to
gB, IgA to gB, IgG to AD-2 and IgA to AD-2. Cut off
values are determined as the mean +2SD of all 4 samples.
The table displays all cut off values obtained at the var-
ious dilutions of breast milk.
Figure S4A. Usage of kappa (k) and lambda (l) L-
chains by undiluted human milk antibodies binding to
gB and AD-2 epitope. Statistical differences between the
mean OD values of antibodies containing the indicated
L-chains for binding to gB and AD-2 epitope was
obtained by Mann-Whitney test (**** P < .0001). Figure
S4B. Correlations of kappa (k) and lambda (l) Lchains
usage by human milk antibodies binding to gB and AD-2
epitope. Vertical (AD-2) and horizontal(gB) dotted lines
represent cut offs for negative kappa and negative lambda
samples respectively. Spearman’s correlations and p values
are shown.
Figure S5A. Cells profile SSC v FSC and gate applica-
tion (black box) of unstained NS0 cells (upper) and NS0
cells expressing gB-NT (lower). Figure S5B. Cell surface
expression of gB-NT. Binding of human recombinant
monoclonal antibody 8F9 IgG to parental NS0 cells
(upper) and NS0 cells expressing gB-NT (lower). Black
line represents unstained cells, red represents fluorescence
of cells stained with secondary Ab alone (anti-human
kappa FITC) and blue represents cells stained with 8F9
IgG and secondary Ab.
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